{"id":"NCT01456130","sponsor":"Takeda","briefTitle":"Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes","officialTitle":"A Long-Term, Open-Label Study to Investigate the Long-Term Safety of SYR-322 When Used in Combination With Rapid-Acting Insulin Secretagogues in Subjects With Type 2 Diabetes in Japan","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-11","primaryCompletion":"2013-03","completion":"2013-03","firstPosted":"2011-10-20","resultsPosted":"2014-04-21","lastUpdate":"2014-04-21"},"enrollment":67,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":null},"conditions":["Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Alogliptin","otherNames":["SYR-322","NesinaÂ®"]},{"type":"DRUG","name":"Rapid-acting insulin secretagogue","otherNames":[]}],"arms":[{"label":"Alogliptin","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of alogliptin as an add-on to a rapid-acting insulin secretagogue (medicine that stimulates insulin release) in type 2 diabetic patients with inadequate blood glucose control despite treatment with a rapid-acting insulin secretagogue as well as diet and exercise therapies.","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events (TEAEs)","timeFrame":"52 Weeks","effectByArm":[{"arm":"Alogliptin","deltaMin":57,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":14,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":67},"commonTop":["Nasopharyngitis","Upper respiratory tract inflammation","Constipation","Arthralgia","Bronchitis"]}}